Amaranth Presented Interim Nine-Month Follow-up MAGNITUDE (98 micron) and Two-Year Follow-up APTITUDE (115 micron) Data at EuroPCR Symposium
23. Mai 2018 08:30 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA , May 23, 2018 (GLOBE NEWSWIRE) -- Amaranth Medical, a medical device company developing next-generation bioresorbable scaffolds for the interventional cardiology market, provided...
Amaranth Medical Showcases Breadth of BRS Pipeline at TCT, Unveiling 9-mo Interim Imaging Results from 98 micron MAGNITUDE and Update on 115-micron APTITUDE
25. Oktober 2017 13:21 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Amaranth Medical, a medical device company developing next-generation bioresorbable scaffolds for the interventional cardiology market, will...
Amaranth Medical Initiates Trial of Sub-100-Micron MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold
01. November 2016 08:00 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA , Nov. 01, 2016 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced the initiation of a clinical study of the Company’s latest-generation...
Amaranth Medical 9-Months Clinical and Imaging Results of the FORTITUDE Sirolimus-Eluting Bioresorbable Scaffold Presented at TCT
31. Oktober 2016 12:30 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced that a presentation of the 9-month clinical and imaging results from the...
Amaranth Medical Completes Enrollment in RENASCENT-II Study of 120-Micron APTITUDE™ Sirolimus-Eluting Bioresorbable Scaffold
06. Juni 2016 08:00 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA , June 06, 2016 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced that it completed enrollment in May 2016 in the RENASCENT-II study of its...
Amaranth Medical On Track to Complete Enrollment in RENASCENT-II Study of 120-Micron APTITUDE™ Sirolimus-Eluting Bioresorbable Scaffold in May
18. Mai 2016 03:01 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA , May 18, 2016 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, provided a clinical update on its ongoing RENASCENT-II study of its novel APTITUDE™...
Amaranth Medical Completes MEND-II and RENASCENT Studies and Initiates Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold
15. Oktober 2015 08:00 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA, Oct. 15, 2015 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced that enrollment has successfully concluded in its multi-center, international...
Amaranth Medical Reports Findings from Two FORTITUDE Bioresorbable Scaffold Studies at EuroPCR 2015
18. Mai 2015 15:12 ET
|
Amaranth Medical, Inc.
Mountain View, CA, May 18, 2015 (GLOBE NEWSWIRE) -- Amaranth Medical, a
privately held medical device company, announced plans to report
clinical results from the Company's ongoing trial of...
Amaranth Medical Announces Investment from Boston Scientific
14. Januar 2014 09:14 ET
|
Amaranth Medical, Inc.
Mountain View, CA, Jan. 14, 2014 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, today
announced the closing of an equity investment by Boston Scientific
Corporation...
Amaranth Medical Reports Positive Safety and Feasibility Findings for the FORTITUDE(TM) Bioresorbable Scaffold
28. Oktober 2013 08:00 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company,
presented positive six-month angiographic results from its
first-in-human study...